Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study by Santema, Bernadet T. et al.
\  
 
 
 
 
 
Santema, B. T. et al. (2019) Identifying optimal doses of heart failure 
medications in men compared with women: a prospective, observational, 
cohort study. Lancet, 394, 10205. (doi: 10.1016/S0140-6736(19)31792-1) 
 
The material cannot be used for any other purpose without further 
permission of the publisher and is for private use only. 
 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it.  
 
 
http://eprints.gla.ac.uk/193969/  
 
 
 
 
 
 
   Deposited on 27 August 2019 
 
 
 
 
 
Enlighten – Research publications by members of the University of       
           Glasgow 
http://eprints.gla.ac.uk  
 
1 
 
Identifying optimal doses of heart failure medications in men compared 1 
with women: a prospective, observational cohort study 2 
 3 
Bernadet T. Santema, MDa, Wouter Ouwerkerk, PhDb,c, Jasper Tromp, MD/PhDa,b,  4 
Iziah E. Sama, PhDa, Alice Ravera, MDa,d, Prof. Vera Regitz-Zagrosek, MD/PhDe,  5 
Prof. Hans Hillege, MD/PhDa, Prof. Nilesh J. Samani, FRCPf,g, Prof. Faiez Zannad, MD/PhDh,  6 
Prof. Kenneth Dickstein, MD/PhDi,j, Prof. Chim C. Lang, MDk, Prof. John G. Cleland, MDl,m,  7 
Jozine M. Ter Maaten, MD/PhDa, Prof. Marco Metra, MDd, Prof. Stefan D. Anker, MD/PhDn,  8 
Pim van der Harst, MD/PhD1, Prof. Leong L. Ng, MDf,g, Prof. Peter van der Meer, MD/PhDa,  9 
Prof. Dirk J. van Veldhuisen, MD/PhDa, Sven Meyer, MD/PhDo,  10 
Prof. Carolyn S.P. Lam, MD/PhD*a,b, Prof. Adriaan A. Voors, MD/PhDa 11 
 12 
*on behalf of the ASIAN-HF investigators, Appendix S1 13 
Total word count: 3685 14 
Abstract word count: 301 15 
a. Department of Cardiology, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands 16 
b. National Heart Centre Singapore, Hospital Drive, Singapore 169659  17 
c. Dept of Dermatology, Amsterdam UMC, University of Amsterdam, Amsterdam Infection & Immunity Institute, 18 
Amsterdam, The Netherlands 19 
d. Institute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, 20 
University of Brescia, Piazza del Mercato, 15, 25121 Brescia, Italy 21 
e. Charité - Universitaetsmedizin Berlin, Institute for Gender in Medicine, CCR, DZHK, partner site Berlin, Hessische Str 3-22 
4, 10115, Berlin, Germany 23 
f. Department of Cardiovascular Sciences, University of Leicester, Groby Road, Leicester, LE3 9QP, UK 24 
g. NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Groby Road Leicester, LE3 9QP, UK 25 
h. INSERM, Centre d’Investigations Cliniques Plurithe´matique 1433, INSERM U1116, Universite´ de Lorraine, CHRU de 26 
Nancy, F-CRIN INI-CRCT, Nancy, France 27 
i. University of Bergen, 5007 Bergen, Norway 28 
j. Stavanger University Hospital, Gerd-Ragna Bloch Thorsens Gate 8, 4011 Stavanger, Norway 29 
k. School of Medicine Centre for Cardiovascular and Lung Biology, Division of Molecular and Clinical Medicine, University 30 
of Dundee, Ninewells Hospital & Medical School, Dundee, DD1 9SY, UK 31 
l. National Heart & Lung Institute, Royal Brompton & Harefield Hospitals, Imperial College, Sydney St, Chelsea, London 32 
SW3 6NP, UK 33 
m. Robertson Institute of Biostatistics and Clinical Trials Unit, University of Glasgow, University Avenue, Glasgow G12 34 
8QQ, UK 35 
n. Department of Cardiology (CVK); and Berlin Institute of Health Center for Regenerative Therapies (BCRT); German 36 
Centre for Cardiovascular Research (DZHK) partner site Berlin; Charité Universitätsmedizin Berlin, Germany 37 
o. Heart Center Oldenburg. Department of Cardiology. European Medical School Oldenburg-Groningen. Carl von Ossietzky 38 
University Oldenburg. Oldenburg. Germany.  39 
2 
 
Address for correspondence: 40 
Prof. Dr. A.A. Voors 41 
Department of Cardiology 42 
University Medical Center Groningen 43 
Hanzeplein 1, 9713 GZ, Groningen, The Netherlands 44 
Tel: +31 (0)50 3612355 45 
Fax: +31 (0)50 3618062 46 
E-mail: a.a.voors@umcg.nl 47 
48 
3 
 
Abstract 49 
Background: Guideline-recommended doses of angiotensin-converting-enzyme (ACE) 50 
inhibitors/angiotensin-receptor blockers (ARBs) and beta-blockers are similar for men and women 51 
with heart failure with reduced ejection fraction (HFrEF), even though there are known sex differences 52 
in pharmacokinetics of these drugs. We hypothesized that there may be sex differences in the optimal 53 
dose of ACE-inhibitors/ARBs and beta-blockers in patients with HFrEF.  54 
Methods: We performed a post-hoc-analysis of BIOSTAT-CHF, a prospective study of HF patients in 55 
whom initiation and up-titration of ACE-inhibitors/ARBs and beta-blockers was encouraged by 56 
protocol. Findings were validated in an independent cohort (ASIAN-HF) of 3,539 men and 961 57 
women with HFrEF. 58 
Findings: Among 1,308 men and 402 women with HFrEF from BIOSTAT-CHF, women were older 59 
(74 vs. 70 years, p<0·001), and had lower body weight (72 vs. 85 kg, p<0·001) and height (162 vs. 60 
174 cm, p<0·001) than men, although body mass index did not differ significantly. A similar % of 61 
men and women reached guideline-recommended target doses of ACE-inhibitors/ARBs (25 vs. 23%; 62 
p=0·61) and beta-blockers (14 vs. 13%; p=0·54). In men, the lowest hazards of death and/or HF-63 
hospitalization occurred at 100% of the recommended dose of ACE-inhibitors/ARBs and beta-64 
blockers, but women showed a ~30% lower risk at only 50% of the recommended doses, with no 65 
further decrease in risk at higher dose levels. These sex differences were still present after adjusting 66 
for clinical covariates including age and body surface area. In the ASIAN-HF registry, similar patterns 67 
were observed for both ACE-inhibitors/ARBs and beta-blockers, with women having a ~30% lower 68 
risk at 50% of the recommended doses, with no further benefit at higher dose levels.  69 
Interpretation: This study suggests that women with HFrEF may need lower doses of ACE-70 
inhibitors/ARBs and beta-blockers as compared with men, and brings into question what true ‘optimal 71 
medical therapy’ is for women versus men. 72 
Funding: European Commission [FP7-242209-BIOSTAT-CHF]. 73 
Keywords: Heart failure – Sex differences – Women – Uptitration – ACE-inhibitor – Beta-blocker 74 
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Research in context 75 
Evidence before this study 76 
We searched PubMed from Jan 1, 1980, to Jan 31, 2019. with the search terms “heart failure”, “sex 77 
differences”, “gender differences”, “women”, “men”, “outcome”, “mortality”, “hospitalization”, 78 
“drugs”, “medication”, “dose”, “angiotensin-converting enzyme inhibitors”, “angiotensin-receptor 79 
blockers”, and “beta-blockers”. There were no studies that directly compared the optimal dose levels 80 
of current evidence-based drugs on a continuous scale, in relation to clinical outcome of men and 81 
women with heart failure with reduced ejection fraction separately. 82 
Added value of this study 83 
To our knowledge, this is the first study to show that there are striking sex differences in the optimal 84 
dose levels of angiotensin-converting-enzyme inhibitors/angiotensin-receptor blockers and beta-85 
blockers in patients with heart failure with reduced ejection fraction, where women had the lowest risk 86 
of death and/or heart failure hospitalization at half the guideline-recommended doses as compared 87 
with men. 88 
Implications of all available evidence 89 
Due to the under-representation of women with heart failure with reduced ejection fraction in all 90 
previous clinical drug trials, and in the absence of prospective sex-specific dose-finding clinical trials 91 
of current therapies, this is the best available evidence with regards to the optimal dose levels of heart 92 
failure medication in men and women separately. These findings should also prompt similar studies in 93 
other cardiovascular disease areas.  94 
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Introduction 95 
Angiotensin-converting-enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARBs) and beta-96 
blockers are the cornerstone of therapy for patients with heart failure with reduced ejection fraction 97 
(HFrEF).1 Current HF guidelines recommend up-titration of ACE-inhibitors/ARBs and beta-blockers 98 
to the same target doses in men and women (Table 1). These sex-neutral target doses were 99 
recommended despite findings from several pharmacological studies indicating that with the same 100 
dose, the maximum plasma concentrations of ACE-inhibitors, ARBs and beta-blockers were up to 2·5 101 
times higher in women as compared to men.2–4 Women generally have lower body weights, a higher 102 
proportion of body fat, and a lower plasma volume. This may contribute to a longer duration of action 103 
of lipophilic drugs, and higher peak plasma concentrations of hydrophilic drugs in women.4,5 104 
Moreover, lower cardiac output in women results in lower hepatic flow and lower glomerular filtration 105 
rate, and women have lower expression of some drug-specific CYP-isoenzymes, which could also 106 
contribute to higher plasma levels of both hydrophilic and lipophilic drugs in women.6,7 Supporting 107 
these considerations, studies with beta-blockers showed different pharmacodynamic effects with a 108 
greater reduction in heart rate and blood pressure in women compared to men using similar doses.8,9 In 109 
addition, women have a 50-70% greater risk in experiencing adverse drug reactions compared to men, 110 
and these adverse events are generally more serious in women.4,5,9  111 
We tested this hypothesis in the prospective multinational European chronic HF cohort of the BIOlogy 112 
Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF), and validated our findings in 113 
the independent multinational chronic HF cohort of Asian Sudden Cardiac Death in Heart Failure 114 
(ASIAN-HF). 115 
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Methods 116 
Patient population and study design 117 
The design and primary results of BIOSTAT-CHF have been previously published.10,11 Briefly, 118 
BIOSTAT-CHF was a multinational, prospective, observational study to evaluate which patients will 119 
have a poor clinical outcome despite evidence-based heart failure treatment, in which we have 120 
performed a post-hoc analysis. A total of 2,516 patients were included who were on suboptimal HF 121 
therapy (not receiving, or receiving ≤50% of target dose of ACE-inhibitors/ARBs and/or beta-122 
blockers) between 2010-2012. Treating physicians were encouraged to initiate and/or up-titrate these 123 
drugs during the first three months after inclusion; the optimization phase. Target doses of the 124 
individual drugs are summarized in Supplementary Table 1.1 The subsequent six months were 125 
considered as the maintenance phase. At nine months, a second study visit was performed in which the 126 
use of heart failure medication doses at three and nine months was recorded again. The fraction of the 127 
target dose that was achieved after the up-titration period at three months was presented as a 128 
percentage ranging from 0 to ≥100%, and further categorized into four groups: 0, 1-49, 50-99% or 129 
≥100% of recommended target dose. We attempted to record the treating physicians’ reason for not 130 
up-titrating patients to target doses (Supplementary Material). Since the European Society of 131 
Cardiology guidelines of 2008 only recommended the use of MRA in patients who have been in New 132 
York Heart Association (NYHA) class IV in the past 6 months (level of evidence B), no specific MRA 133 
up-titration strategy was used in BIOSTAT-CHF. In our analyses, only patients with a left ventricular 134 
ejection fraction (LVEF) <40% were included, in accordance with current guideline-recommended 135 
therapies (n=1,819).1 Patients who died within the first three months (the up-titration phase) were 136 
excluded (n=109). A flow diagram is displayed in Supplementary Figure 1. Baseline characteristics of 137 
the patients that were included and excluded for our study is presented in Supplementary Table 2. 138 
Renal disease was defined as an estimated glomerular filtration rate below 60 mL/min/1·73m2. 139 
Primary outcome was a composite of time to all-cause mortality or HF hospitalization. After the 140 
second study visit at nine months, patients were followed either by standard clinic follow-up, or 141 
telephone contact every six months until the end of study. The protocol of BIOSTAT-CHF used clear 142 
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endpoint definitions, a structured case report form, and source data of all sites were closely monitored. 143 
The median follow-up duration for the primary endpoint was 21 months (first and third quartile [Q1-144 
Q3] of 15-27 months).  145 
The results of this study were validated in ASIAN-HF, a prospective observational study of 5,276 146 
patients with symptomatic HF and LVEF≤40% from 11 Asian regions, in which maximally tolerated 147 
doses of HF medications were closely recorded and patients were followed up for outcomes 148 
(independently adjudicated).12 Target doses of beta-blockers and ACE-inhibitors/ARBs were defined 149 
using the same international standards as for BIOSTAT-CHF. Patients with missing outcome date 150 
(n=582) or incomplete data about the dose level of HF medication (n=194) were excluded. Baseline 151 
characteristics of patients that were included and excluded from ASIAN-HF for our study is presented 152 
in Supplementary Table 3. 153 
Both BIOSTAT-CHF and ASIAN-HF comply with the Declaration of Helsinki, and medical ethics 154 
committee of participating centers approved the study. All patients provided written informed consent.  155 
Statistical analyses 156 
Normally distributed continuous variables were reported as means ± standard deviation and non-157 
normally distributed variables as median (Q1-Q3). Categorical variables were presented as numbers 158 
with percentages. Student’s t-tests, Chi-square tests and Mann-Whitney U tests were used for group 159 
comparisons. Cox proportional hazard models were used to calculate hazard ratios (HR), adjusted for 160 
the effect of potential confounders, with patients using ≥100% of the recommended dose as the 161 
reference category. The multivariable risk model of BIOSTAT-CHF for the composite endpoint (death 162 
and/or HF hospitalization) was used, which contains age, previous HF hospitalization, systolic blood 163 
pressure, presence of peripheral edema, N-terminal pro-brain natriuretic peptide (NT-proBNP), 164 
hemoglobin, sodium, high-density lipoprotein, and the use of beta-blockers at baseline.13 In a separate 165 
multivariable model, outcome was adjusted for body surface area (BSA) using the formula of Du Bois 166 
& Du Bois.14 Since the range of 1-49% and 50-99% of recommended dose in the Cox regression 167 
models is quite broad, but chosen to keep a sufficient number of patients within all four dose 168 
categories, a density plot of the patients using specific dose levels in BIOSTAT-CHF (in blue) and 169 
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ASIAN-HF (in red) is displayed as Supplementary Figure 2, showing that the large majority of 170 
patients in the 50-99% dose category actually uses 50% of recommended dose. 171 
Because BIOSTAT-CHF and ASIAN-HF are not randomized controlled trials, we adjusted for 172 
treatment indication bias.15 All analyses of the effect of up-titration on mortality and/or HF 173 
hospitalization risk were inversely weighted with the probability of the given treatment.16 The given 174 
treatment is defined as successful up-titration to ≥50% of European Society of Cardiology–175 
recommended doses for ACE-inhibitor/ARBs or beta-blockers or not.11 The probability of given 176 
treatment for a specific patient was modelled using a penalized (LASSO) logistic regression model.17 177 
All available covariates were considered as predictor variables for successful up-titration. We 178 
averaged the probabilities over five imputation sets. The weights were calculated by the inverse of the 179 
probability for those who were successfully treated, or the (1-probability)ˆ-1 for those who were not.  180 
In order to compare the non-linear risk of the composite endpoint between men and women along the 181 
continuum of fractions of target doses, smoothing natural cubic splines were used. We modelled the 182 
composite endpoint in men and women using Cox proportional hazard models with dosages on a 183 
continuous scale using natural regression splines added to the sex effects and their interaction. The 184 
optimal degrees of freedom were determined based on the Bayesian information criterion defined 185 
as: BIC=−2 * log(Likelihood) + number of parameters * log(n), which put a penalty on the number of 186 
parameters.18 The lines in Figure 1 and 2 are based on the Cox regression models in men and women 187 
on that specific dose level, compared to the hazard of the total population (men and women combined) 188 
on the median dose.  189 
Further exploratory analysis was performed using subpopulation treatment effect pattern plots 190 
(STEPP). STEPP is a robust method for exploring differences in treatment effect between two 191 
subgroups (in this study men versus women), and was performed to validate the findings from the 192 
cubic splines. STEPP divides the group of men and women into smaller subgroups who use different 193 
% of target dose (on the x-axis), and compares every subgroup with overlap of around 100 patients to 194 
the next subgroup, until every patient has been included in at least one of the subgroups.19,20 This 195 
approach with overlapping subgroups increases the precision of the estimated treatment effect. The 196 
figures display both the individual treatment effect in men and women, combined with a plot below, 197 
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showing the ratio of the Relative Risk of women divided by the Relative Risk in men, resulting in a 198 
Hazard Ratio for women compared with men, including confidence intervals of this ratio. A two-tailed 199 
p-value of <0·05 was considered statistically significant. Statistical analyses were conducted using R, 200 
A Language and Environment for Statistical Computing, version 3.4.1 (R Foundation for Statistical 201 
Computing, Vienna, Austria). 202 
Role of the funding source 203 
This study was supported by a grant from the European Committee. However, they had no role in the 204 
study design; in the collection, analysis, and interpretation of data; in writing of the report; and in the 205 
decision to submit the paper for publication. The corresponding author had full access to all the data in 206 
the study and had final responsibility for the decision to submit for publication.  207 
Results 208 
Clinical characteristics 209 
A total of 1,710 patients from BIOSTAT-CHF were studied, of whom 402 (24%) were women. 210 
Baseline characteristics of men and women are presented in Table 2. At baseline, women were older 211 
(74 versus 70 years, p<0·001), had lower body weight (72 versus 85 kg, p<0·001) and height (162 212 
versus 174 cm, p<0·001), although BMI did not differ significantly (27·3 versus 27·9, p=0·06). 213 
Women less often had a history of smoking (28% versus 65%, p<0·001) and less coronary artery 214 
disease (35% versus 48%, p<0·001), atrial fibrillation (35% versus 44%, p=0·002), and renal disease 215 
(19% versus 25%, p=0·02) as compared with men. Women reported lower quality of life than men 216 
(median overall score of 44 versus 54 in men, p<0·001), despite similar levels of NT-proBNP (2,724 217 
versus 2,484 pg/mL in men, p=0·18). The use of MRA was higher in men than in women, both at 218 
baseline (59% versus 48% in women, p<0·001), and at follow-up (55% versus 47% in women, 219 
p=0·006). 220 
Up-titration of medication 221 
At baseline, there were no significant differences in the use of ACE-inhibitors/ARBs between the 222 
sexes, with similarly small proportions already at target doses at baseline (Table 2). Beta-blockers 223 
were more frequently used at baseline than ACE-inhibitors/ARBs, and more often in men than in 224 
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women, with similarly small proportions already at target dose at baseline. The proportion of men and 225 
women who reached the recommended target dose after the first three months of the study was also 226 
similar. At the follow-up visit at 9 months, blood pressure and heart rate were similar between men 227 
and women (Supplementary Table 4). An overview of the most frequently prescribed individual HF 228 
drugs in men and women is presented in Supplementary Table 5. 229 
With regards to men, the univariable Cox regression model showed the highest risk of death and/or HF 230 
hospitalization when they did not receive any dose of ACE-inhibitor/ARBs or beta-blockers, a lower 231 
risk when they reached 1-49% or 50-99% of target dose, and lowest risk when they reached ≥100% of 232 
target dose (reference category) (Table 3). In multivariable analysis, men did not have a survival 233 
benefit when they used lower doses as compared to those on target dose. With regards to women, 234 
those treated with 50-99% of the recommended target dose had the lowest risk of death and/or HF 235 
hospitalization, even compared to those at 100% of the target dose for both ACE-inhibitor/ARBs and 236 
beta-blockers, also after multivariable adjustment (Table 3). 237 
Cubic splines and STEPP analyses 238 
Figure 1 shows sex-stratified splines according to dose of beta-blockers and ACE-inhibitors/ARBs, 239 
ranging from 1-100%, using the population mean as the reference. For beta-blockers, there was a U-240 
shaped risk curve among women, with an optimal dose level for women around 60% of recommended 241 
target dose (Figure 1A). For men using beta-blockers, a lower risk was observed around both 30% and 242 
100% of target dose. For ACE-inhibitors/ARBs, women had the lowest risk of the composite endpoint 243 
at around 40% of recommended target dose and no further decrease in risk at higher dose levels, 244 
whereas men had the lowest risk at 100% of recommended target dose (p<0·001, Figure 1B). 245 
The STEPP analysis with the fraction of target dose per drug on a continuous scale revealed similar 246 
results compared to the Cox regression models and the splines, with men having a lower risk with 247 
increasing dose levels of ACE-inhibitors/ARBs and beta-blockers, whereas women had the lowest risk 248 
of death and/or HF hospitalization when they used 50% of target dose of ACE-inhibitors/ARBs and 249 
(Supplementary Figure 3). Both sexes had the highest risk of the composite endpoint when they used 250 
no ACE-inhibitors/ARBs or beta-blockers at all.  251 
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Validation analysis 252 
Of the 4,500 patients studied from ASIAN-HF, 961 (21%) were women. Both men and women in the 253 
validation cohort were younger, and had lower body weight and height compared to the European 254 
cohort (Supplementary Table 6). The cubic spline for Asian women using doses of beta-blockers 255 
showed a steep decline in risk of the composite endpoint around 40-50% of recommended dose, with 256 
no further decrease in risk at higher dose levels, whereas the risk in Asian men was lowest when using 257 
100% of recommended target dose of beta-blockers (p<0·001, Figure 2A). The spline of Asian women 258 
using doses of ACE-inhibitors/ARBs showed a decrease in risk for the composite endpoint around 259 
60% of recommended target dose, and no further protective effect at doses higher than 60% (Figure 260 
2B). Asian men did only seem to benefit from ACE-inhibitors/ARBS when using more than 50% of 261 
the recommended dose, and on the whole scale of dose levels, men had a significantly higher risk of 262 
the composite endpoint as compared with women (P<0·001).  263 
Discussion 264 
Drug therapies are of great importance to patients with HFrEF, and uptitration of these drugs to 265 
maximal doses is recommended in current HF guidelines (Table 1). The main finding of the present 266 
study suggests, however, that these doses may not be appropriate in women. Our multinational 267 
observational study showed sex differences in the optimal dose of ACE-inhibitors/ARBs and beta-268 
blockers in patients with HFrEF, where women had the lowest risk of adverse outcomes at lower doses 269 
(half the guideline-recommended doses) as compared to men, with no further decrease in risk at higher 270 
dose levels.  271 
These findings were found in BIOSTAT-CHF, in which patients were included from 11 European 272 
countries, and were validated in an independent HF cohort in which patients were included from 11 273 
Asian regions (ASIAN-HF). These two HF populations did not only differ in ethnic background, but 274 
also differed importantly in other baseline characteristics, with patients from ASIAN-HF being 275 
younger, and having a much lower body weight, height and BMI as compared to the European cohort. 276 
Moreover, known differences in metabolism between Asian and European patients, such as ethnic 277 
differences in the incidence of cytochrome P450 polymorphisms, could have resulted in different 278 
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findings in the optimal dose levels of patients included in ASIAN-HF as compared to those in the 279 
European cohort.21 Despite differences in baseline characteristics and ethnicity, similar patterns in 280 
optimal dose levels for men and women were observed in ASIAN-HF and BIOSTAT-CHF; thus 281 
strengthening our hypothesis that there are intrinsic sex differences observed in different regions 282 
worldwide. 283 
Important sex differences in relation to the use of heart failure medication has been previously shown 284 
by the Digitalis Investigation Group (DIG) trial. This randomized, placebo-controlled trial was first 285 
published in 1997, showing less overall- and HF-related hospitalizations in patients using digoxin 286 
(versus placebo) in patients with stable HF and LVEF<45%.22 Therefore, the use of digoxin was 287 
recommended in both the United States and the European guidelines. However, a post-hoc subgroup 288 
analysis showed a significantly higher absolute risk of death in women, and a non-significant 289 
reduction in the risk of death among men (p=0·014 for interaction).23 Even though men used slightly 290 
higher doses of digoxin in this trial (0·0093 mg per unit of body-mass index versus 0·0084 mg in 291 
women), higher serum digoxin levels were found in women one month after study entry (0·9 ng/mL 292 
versus 0·8 ng/mL, p=0·007). Unfortunately, there was insufficient statistical power to test for an 293 
interaction between sex, the use of digoxin, and sex differences in serum digoxin levels, since serum 294 
levels of digoxin were only measured in a small subpopulation (less than one third) of the trial 295 
participants.23 There might still be favorable effects of lower doses of digoxin (and accompanying 296 
lower serum digoxin levels) in patients with HFrEF using currently recommended therapies, which 297 
will be further investigated in a randomized clinical trial.24 298 
The randomized trial HEAAL, in which high versus low-doses of losartan in HF were compared, 299 
concluded that patients treated with the high dose level had the best clinical outcome.25 However, a 300 
sex-stratified subgroup analysis comparing high versus low dose showed a HR of 0·86 (0·77-0·96) for 301 
men in favor of the higher dose of losartan, and no significant difference between the two dose levels 302 
in women (HR 1·02, 95% CI 0·85-1·23), with a p-value for interaction of 0·10, even though this study 303 
was not powered for subgroup analyses. Moreover, results from ATLAS comparing high and low dose 304 
of lisinopril observed that men had significantly lower all-cause mortality using the higher dose levels 305 
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(32·5 to 35 mg daily), whereas in women a trend towards better survival in the lower dose (2·5 to 5·0 306 
mg daily) was observed (p-value for interaction was not provided).26  307 
As described previously, there are several well-established pharmacokinetic sex differences that could 308 
contribute to differences in optimal doses of HF medications for men and women. In our study, 309 
women were older, and had a significantly lower body weight and height than men. A study in healthy 310 
men and women observed that after administration of one dose of 100mg metoprolol, the area under 311 
the concentration-time curve (AUC) was 417 mcg·h/L in men and 867 mcg·h/L in women. The large 312 
difference in body weight (83·9 ± 10·7 kg in men and 62·0 ± 7·3 kg in women) and clearance rate 313 
between men (253 L/h) and women (101 L/h) seemed to be important contributors to these observed 314 
differences in AUC. Based on these findings, a dose reduction for metoprolol of 50% in women was 315 
recommended by the authors, which is strikingly similar to the findings in the present study, even after 316 
adjustment for BSA.2  317 
Another hypothesis is that women are more sensitive, i.e. have a greater clinical response to drugs than 318 
men, even if plasma concentrations were similar between the sexes.4 The effect of sex hormones on 319 
specific drugs, but also how drugs effects are being experienced by men and women are still poorly 320 
understood, and could potentially contribute to higher reporting rates of adverse events in women.27  321 
Sex differences with regards to other HF therapies are previously observed in different responses to 322 
cardiac resynchronization therapy (CRT) between men and women, in which women had a better 323 
response to CRT than men.28 However, to our knowledge, no such analyses are available with respect 324 
to medical treatment in HF.  325 
It should be noted that previous results from the CHAMP-HF registry showed that women with HFrEF 326 
are often not treated with current guideline recommended therapies, in the absence of absolute 327 
contraindications to these therapies.29 Moreover, the TRED-HF trial showed that discontinuation of 328 
HFrEF therapies, even in patients with recovered LVEF, have deleterious effects.30 We therefore 329 
emphasize that the findings of the current study should not be misinterpreted as an excuse to 330 
undertreat women with HFrEF. Instead, we suggest that a one-size-fits-all approach may not be 331 
14 
 
optimal in the treatment of men and women with HFrEF, but that the dose levels of HF medication in 332 
women should perhaps not be as high as in men.  333 
Limitations 334 
The present study is limited by its post-hoc design. We could not assess dose-related side effects of 335 
drugs, despite attempting to record physicians’ reasons for lack of up-titration. A greater frequency of 336 
adverse drug reactions in women compared to men could impact the maximum tolerated dose and 337 
warrants future study. We did not measure serum levels of HF medications, which could have 338 
provided more insight into the underlying mechanisms of the present findings. The sample size of 339 
women in BIOSTAT-CHF and ASIAN-HF was relatively low as compared to the number of men, 340 
which is very common in HFrEF studies. The number of patients reaching target doses of ACE-341 
inhibitors/ARBs and beta-blockers is not comparable to the numbers of patients reaching target doses 342 
in randomized clinical trials, since our study reflects real-world up-titration instead of trial protocol 343 
targets. We have performed the analyses for ACE-inhibitors/ARBs and beta-blockers, and did not 344 
further differentiate between all individual drugs within these drug categories, even though the 345 
pharmacokinetic and pharmacodynamic characteristics of the individual drugs within these categories 346 
could differ. Even though we have adjusted for multiple potential confounders in our multivariable 347 
regression models, we cannot exclude the possibility that our findings could be influenced by other 348 
previously described sex differences in baseline characteristics, such as the higher use of MRA in 349 
men, or unknown confounding factors. The observation of the lower risk in men that used only ~30% 350 
of recommended beta-blocker dose, as was observed in the spline (Figure 1) and Cox regression 351 
models (Table 3), is not fully understood and might be caused by overfitting of the model. This 352 
observation was neither found in the STEPP analysis, nor in the validation cohort of ASIAN-HF. 353 
To our knowledge, this is the first study to describe sex-specific outcome in relation to the prescribed 354 
dose levels of HF medications. These findings may have important implications for sex-specific target 355 
doses in HF, and should be validated in dose-finding sex-stratified prospective studies. It is, however, 356 
unlikely that these sex-specific dose-finding trials of current HFrEF therapies will be performed. This 357 
15 
 
study also underlines the importance of performing pre-specified sex-specific analyses in all drug 358 
trials.  359 
Conclusion 360 
The present study provides evidence supporting the hypothesis that women with HFrEF may have the 361 
best outcomes with lower doses of ACE-inhibitors/ARBs and beta-blockers as compared with men, 362 
and lower doses than recommended in international HF guidelines. This study brings into question 363 
what true ‘optimal medical therapy’ is for women versus men with HFrEF. 364 
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Figure Legend 483 
Figure 1. Natural cubic splines showing the optimal beta-blocker (1A) and ACE-inhibitor/ARB dose 484 
(1B) ranging from 1-100% of recommended target dose in men and women (BIOSTAT-CHF) for the 485 
composite endpoint all-cause mortality and/or HF hospitalization, compared to the hazard of the total 486 
population (men and women combined) on the median dose. Median follow-up duration was 21 487 
months (IQR 15-27 months). The smoothened areas at the bottom of both figures represent the density 488 
of men (blue) and women (red) taking that specific dose level. The p-value represents the interaction 489 
of sex and treatment in the Cox regression model. ACE=angiotensin converting enzyme inhibitor, 490 
ARB=angiotensin receptor blocker, HF=heart failure.  491 
Figure 2. Validation of optimal beta-blocker (2A) and ACE-inhibitor/ARB dose (2B) ranging from 1-492 
100% of recommended target dose in men and women in ASIAN-HF, for the composite endpoint all-493 
cause mortality or HF hospitalization, compared to the hazard of the total population (men and women 494 
combined) on the median dose. Median follow-up duration was 14 months (IQR 7-25 months). The 495 
smoothened areas at the bottom of both figures represent the density of men (blue) and women (red) 496 
taking that specific dose level. The p-value represents the interaction of sex and treatment in the Cox 497 
regression model. ACE=angiotensin converting enzyme inhibitor, ARB=angiotensin receptor blocker, 498 
HF=heart failure. 499 
 500 
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Table 1. Overview of sex-specific details of drug trials on which the international heart failure guidelines are based. 504 
Drug 
class 
Study Published  
(year) 
Countries Drug Target 
dose 
Actual 
mean dose 
used 
Eligibility 
criteria 
LVEF Baseline 
characteristics 
Background 
medication 
% 
women  
No. of  
women 
 
Primary 
endpoint 
Sex-specific outcome 
ACE-i CONSENSUS 1987 Finland, 
Norway, and 
Sweden 
Enalapril 20mg 
b.i.d. 
9mg b.i.d. 
28% on 
target dose 
NYHA IV 
only,  
≤35% Mean age 71 years, 
73% ischaemic heart 
disease, 50% AF 
98% diuretic 
93% digoxin 
3% b-blocker 
55% vasodilator 
30 74 Mortality Significant benefit in men, 
not in women 
SOLVD-
Treatment 
1991 U.S.A., 
Canada, and 
Belgium 
Enalapril 10mg 
b.i.d. 
8·4mg 
b.i.d. 
49% on 
target dose 
<80 years, 
NYHA I-IV 
≤35% Mean age 61 years, 
mean LVEF 25%, 
71% ischaemic heart 
disease 
85% diuretic 
67% digoxin 
8% b-blocker 
51% vasodilators 
20 505 Mortality  Significant benefit in men, 
trend towards benefit in 
women 
ARB Val-HeFT 2001 16 countries: 
U.S.A., 
Australia, 
Europe, 
South Africa 
Valsartan 160mg 
b.i.d. 
127 b.i.d. 
84% on 
target dose 
NYHA II-IV, 
Stable, 
chronic HF 
<40% Mean age 63 years, 
57% ischaemic heart 
disease 
93% ACE-i 
86% diuretic 
67% digoxin 
35% b-blocker 
 
20 1,003 Mortality or HF 
hospitalisation/
ED presentation 
Significant benefit in men, 
trend towards benefit in 
women 
CHARM-
Added 
2003 26 countries 
U.S.A./Euro
pe 
Candesartan 32mg 
q.d. 
24mg q.d. 
61% on 
target dose 
NYHA II-IV ≤40% Mean age 64 years, 
62% ischaemic heart 
disease, 77% 
previous HF 
hospitalisation 
100% ACE-i 
90% diuretic 
58% digoxin 
55% b-blocker 
37% vasodilators 
21 542 Cardiovascular 
death or HF 
hospitalisation 
CHARM low-LVEF trials 
combined: 
No sex difference in primary 
endpoint, p for interaction 
0·95 
CHARM-
Alternative 
2003 26 countries 
U.S.A./Euro
pe 
Candesartan 32mg 
q.d. 
23mg q.d. 
59% on 
target dose 
NYHA II-IV, 
ACE-i 
intolerance 
≤40% Mean age 67 years, 
68% ischaemic heart 
disease, 68% 
previous HF 
hospitalisation 
0% ACE-i 
85% diuretic 
55% b-blocker 
46% digoxin 
43% vasodilators 
32 646 Cardiovascular 
death or HF 
hospitalisation 
β- 
blocker 
U.S. 
Carvedilol HF 
1996 U.S.A. Carvedilol 25-
50mg 
b.i.d. 
23mg b.i.d. 
80% on 
target dose 
Chronic HF, 
NYHA II-IV 
≤35% Mean age 58 years, 
mean LVEF 23% 
95% ACE-i 
95% diuretic 
91% digoxin 
32% vasodilator 
23 256 Mortality  HR 0·41 (0·22-0·80) in men 
HR 0·23 (0·07-0·69) in 
women 
CIBIS II 1999 18 European 
countries 
Bisoprolol 10mg 
q.d. 
8·5mg q.d. 
63% on 
target dose 
 
<80 years, 
NYHA III-
IV, stable, 
chronic HF 
≤35% Mean age 61 years, 
50% ischaemic heart 
disease 
 
96% ACE-i 
99% diuretic 
52% digoxin 
58% vasodilator 
19 515 Mortality Significant benefit in men 
and women 
MERIT-HF 1999 13 European 
countries and 
U.S.A. 
Metoprolol 200mg 
q.d. 
159mg q.d. 
64% on 
target dose 
Age 40-80, 
NYHA II-IV, 
stable, 
chronic HF 
≤40% Mean age 64 years, 
66% ischaemic heart 
disease 
96% ACE-i/ARB 
91% diuretic 
64% digoxin 
 
23 898 Mortality or all-
cause 
hospitalisation 
Significant benefit in men, 
not in women 
COPERNICUS 2001 21 countries 
in Europe, 
Asia, Africa, 
Australia, 
U.S.A., and 
South 
America 
Carvedilol 25mg 
b.i.d. 
18mg b.i.d. 
65% on 
target dose 
Low LVEF, 
inclusion of 
both inpatient 
and outpatient 
clinic 
<25% Mean age 63 years, 
mean LVEF 20% 
97% ACE-i/ARB 
99% diuretic 
66% digitalis 
 
20 465 Mortality Significant benefit in men, 
trend towards benefit in 
women 
25 
 
SENIORS 2005 11 European 
countries  
Nebivolol 10 mg 
q.d. 
7·7mg q.d. 
68% on 
target dose 
Age ≥70 
years, stable, 
chronic HF 
≤35% 
or HF 
hospita
lisation 
in the 
previou
s year 
Mean age 76 years, 
68% ischaemic heart 
disease 
82% ACE-I 
86% diuretic 
39% digoxin 
37 785 Mortality or 
cardiovascular 
hospital 
admission 
HR 0·93 (0·78-1·11) in men  
HR 0·72 (0·55-0·93) in 
women 
p for interaction 0·11 
ACE-i=angiotensin converting enzyme inhibitor, ARB=angiotensin receptor blocker, b.i.d.=bis in die (twice a day), CHARM-Added=Candesartan in heart failure: Assessment of reduction in mortality and morbidity-505 
Added, , CHARM-Alternative= Candesartan in heart failure: Assessment of reduction in mortality and morbidity-Alternative, CIBIS II= Cardiac Insufficiency Bisoprolol Study II, CONSENSUS=Cooperative North 506 
Scandinavian Enalapril Survival Study, COPERNICUS= Carvedilol Prospective Randomized Cumulative Survival, ED=emergency department, HF=heart failure, HR=hazard ratio, LVEF=left ventricular ejection 507 
fraction, MERIT-HF= Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure, No.=number, NYHA=New York Heart Association,  q.d.=quaque die (once a day), SENIORS=Study of the Effects 508 
of Nebivolol Intervention on Outcomes and Rehospitalisations in Seniors with Heart Failure, SOLVD-Treatment=Studies of Left Ventricular Dysfunction, U.S.A.=United States of America, Val-HeFT=Valsartan Heart 509 
Failure Trial. 510 
 511 
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Table 2. Baseline characteristics of men and women in BIOSTAT-CHF. 512 
 Men Women p-value 
 (n=1,308) (n=402)  
Clinical    
       Age  70 ± 12 74 ± 12 <0·001 
       Weight (kg) 85 ± 18 72 ± 16 <0·001 
       Height (cm) 174 ± 8 162 ± 7 <0·001 
       BMI (kg/m2) 27·9 ± 5·2 27·3 ± 5·8 0·06 
       NYHA (%)   0·27 
I 120 (10) 34 (10)  
II 639 (55) 172 (49)  
III 372 (32) 130 (37)  
IV 38 (3) 12 (3)  
       LVEF, % 27 ± 7 29 ± 6 <0·001 
       Systolic blood pressure, mmHg  123 ± 20 126 ± 23 0·002 
       Diastolic blood pressure, mmHg  76 ± 12 75 ± 13 0·21 
       Pulse pressure, mmHg 47 ± 15 52 ± 17 <0·001 
       Heart rate, beats/min  82 ± 21 83 ± 20 0·32 
       Smoking (%)   <0·001 
                     Never 371 (28) 245 (61)  
                     Past 725 (56) 114 (28)  
                     Current 210 (16) 43 (11)  
History of (%)    
       Coronary artery disease* 631 (48) 139 (35) <0·001 
       Valvular surgery  95 (7) 25 (6) 0·55 
       Atrial fibrillation 574 (44) 140 (35) 0·002 
       Stroke  111 (9) 30 (8) 0·58 
       Peripheral art. disease  140 (11) 22 (6) 0·002 
       Hypertension 759 (58) 253 (63) 0·10 
       Diabetes mellitus  431 (33) 109 (27) 0·03 
       COPD  236 (18) 52 (13) 0·02 
       Renal disease  332 (25) 78 (19) 0·02 
Physical examination (%)    
       Rales  638 (50) 205 (52) 0·44 
       Edema  595 (55) 175 (54) 0·75 
       Orthopnea 388 (30) 137 (34) 0·10 
       Hepatomegaly  206 (16) 40 (10) 0·005 
Quality of life    
       Functional status score 57 [36, 77] 46 [29, 64] <0·001 
       Clinical summary score 52 [33, 71] 42 [27, 60] <0·001 
       Overall score 54 [36, 71] 44 [31, 60] <0·001 
Laboratory data    
       NT-proBNP (pg/mL) 2484 [1073, 5032] 2724 [1193, 5906] 0·18 
       Hemoglobin (g/dL) 13·9 [12·4, 14·9] 12·8 [11·8, 13·8] <0·001 
       Creatinine (µmol/L) 106 [88, 130] 88 [72, 109] <0·001 
       Sodium (mmol/L) 140 [137, 142] 140 [138, 142] 0·12 
27 
 
       Potassium (mmol/L) 4·3 [4·0, 4·6] 4·2 [3·8, 4·6] <0·001 
Medication (%)    
Baseline    
       ACE or ARB 988 (76) 291 (72) 0·23 
       B-Blocker  1123 (86) 328 (82) 0·045 
       MRA 775 (59) 191 (48) <0·001 
       Diuretics 1302 (100) 401 (100) 0·90 
Patients on target dose at baseline    
       ACE or ARB 170 (13) 59 (15) 0·44 
       B-Blocker  66 (5) 21 (5) 0·99 
Median dose at baseline    
       ACE or ARB 0·25 [0·05, 0·50] 0·25 [0·00, 0·50] 0·814 
       B-Blocker 0·25 [0·06, 0·47] 0·25 [0·04, 0·38] 0·612 
Follow-up    
       ACE or ARB 1186 (91) 365 (91) 0·92 
       B-Blocker 1235 (94) 366 (91) 0·05 
       MRA 722 (55) 190 (47) 0·006 
Patients on target dose at follow-up    
       ACE or ARB 304 (23) 99 (25) 0·61 
       B-Blocker  168 (13) 57 (14) 0·54 
Median dose at follow-up    
       ACE or ARB 0·50 [0·25, 0·75] 0·50 [0·25, 0·75] 0·502 
       B-Blocker 0·25 [0·12, 0·50] 0·25 [0·12, 0·50] 0·536 
* Coronary artery disease: previous myocardial infarction, percutaneous coronary intervention (PCI) and/or coronary artery 513 
bypass graft (CABG). BMI=body mass index, NYHA=New York Heart Association, LVEF=left ventricular ejection fraction, 514 
BP = blood pressure, COPD=chronic obstructive pulmonary disease,  NT-proBNP=N-terminal pro-B-type natriuretic peptide, 515 
ACE=angiotensin converting enzyme inhibitor, ARB=angiotensin receptor blocker, MRA=mineralocorticoid receptor 516 
antagonist 517 
 518 
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Table 3. Risk of death or heart failure hospitalization for men and women who received 0, 1-49, 50-99% or ≥100% of recommended ACE-inhibitor/ARB and 519 
beta-blocker dose in BIOSTAT-CHF. 520 
ACE-inhibitor/ARBs Men Women 
 0% 1-49% 50-99% ≥100% 0% 1-49% 50-99% ≥100% 
 n=122 n=476 n=406 n=304 n=37 n=136 n=130 n=99 
Hazard ratio (univariable) 2·29 (2·06-2·55) 1·87 (1·69-2·08) 1·19 (1·06-1·33) Ref. 1·45 (1·18-1·79) 1·04 (0·85-1·26) 0·79 (0·64-0·98) Ref. 
Hazard ratio (multivariable)* 2·18 (1·95-2·43) 1·82 (1·64-2·02) 1·17 (1·04-1·30) Ref. 1·30 (1·05-1·60) 0·85 (0·70-1·05) 0·67 (0·54-0·84) Ref. 
Hazard ratio (multivariable)** 1·09 (0·97-1·23) 1·24 (1·12-1·38) 0·99 (0·88-1·10) Ref. 0·79 (0·63-0·99) 0·90 (0·74-1·11) 0·66 (0·53-0·83) Ref. 
Beta-Blockers Men Women 
 0% 1-49% 50-99% ≥100% 0% 1-49% 50-99% ≥100% 
 
n=73 n=751 n=339 n=145 n=36 n=229 n=91 n=46 
Hazard ratio (univariable) 1·55 (1·39-1·73) 1·11 (1·00-1·23) 1·16 (1·03-1·29) Ref. 1·15 (0·94-1·42) 0·73 (0·59-0·89) 0·63 (0·51-0·79) Ref. 
Hazard ratio (multivariable)* 1·46 (1·31-1·63) 1·08 (0·98-1·20) 1·14 (1·03-1·27) Ref. 1·08 (0·87-1·35) 0·79 (0·65-0·98) 0·74 (0·59-0·92) Ref. 
Hazard ratio (multivariable)** 1·14 (1·03-1·28) 0·95 (0·86-1·06) 1·01 (0·9-1·13) Ref. 1·02 (0·83-1·26) 0·84 (0·69-1·03) 0·76 (0·61-0·95) Ref. 
 521 
*Multivariable model 1: adjusted for body surface are (BSA). 522 
**Multivariable model 2: adjusted for BIOSTAT-CHF model for death and/or heart failure hospitalization including age, heart failure hospitalization in previous year, systolic 523 
blood pressure, presence of peripheral edema, NT-proBNP, hemoglobin, sodium, high-density lipoprotein, and the use of beta-blockers at baseline.524 
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Supplementary Appendix 525 
Table S1. Recommended doses of ACE-inhibitors, ARBs, and beta-blockers in ESC guidelines for patients 526 
with LVEF <40%. 527 
Drug Class Total daily dose 
Captopril  ACE-inhibitor  150 mg 
Enalapril  ACE-inhibitor 20 mg 
Lisinopril  ACE-inhibitor 35 mg 
Ramipril  ACE-inhibitor  10 mg 
Trandolapril  ACE-inhibitor  4 mg 
Perindopril ACE-inhibitor  8 mg 
Candesartan  ARB 32 mg 
Valsartan ARB 320 mg 
Losartan ARB 150 mg 
Bisoprolol Beta-blocker 10 mg 
Carvedilol Beta-blocker 50–100 mg* 
Metoprolol Beta-blocker 200 mg 
Nebivolol Beta-blocker 10 mg 
*A maximum dose of 50mg twice daily can be administered to patients weighting over 85 kg.  528 
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Table S2. Baseline characteristics of included and excluded patients (BIOSTAT-CHF). 529 
 Included Excluded p-value 
 n=1710 n=806 
 
Clinical    
       Age  71 ± 12 76 ± 11 <0·001 
       Women (%) 402 (24) 268 (33) <0·001 
       Weight (kg) 82 ± 18 81 ± 19 0·46 
       Height (cm) 172 ± 9 170 ± 9 <0·001 
       BMI (kg/m2) 27·8 ± 5·4 28·1 ± 5·8 0·15 
       NYHA (%) 
  
0·06 
I 154 (10) 80 (12) 
 
II 811 (54) 330 (48) 
 
III 502 (33) 248 (36) 
 
IV 50 (3) 32 (5) 
 
       LVEF, % 27 ± 7 64 ± 31 <0·001 
       Systolic blood pressure, mmHg  124 ± 21 127 ± 24 <0·001 
       Diastolic blood pressure, mmHg  75 ± 13 74 ± 15 0·001 
       Heart rate, beats/min 82 ± 21 83 ± 22 0·37 
History of (%)    
       Coronary artery disease* 770 (45) 361 (45) 0·94 
       Valvular surgery  120 (7) 59 (7) 0·85 
       Atrial fibrillation 714 (42) 429 (53) <0·001 
       Peripheral art. disease  162 (10) 111 (14) 0·002 
       Hypertension 1012 (59) 557 (69) <0·001 
       Diabetes mellitus  540 (32) 279 (35) 0·14 
       COPD  288 (17) 148 (18) 0·38 
       Renal disease  410 (24) 286 (36) <0·001 
Physical examination (%)    
       Rales  843 (50·3) 448 (58) <0·001 
       Edema  770 (54·8) 486 (70) <0·001 
       Orthopnea 525 (30·7) 354 (44) <0·001 
       Hepatomegaly  246 (14·4) 112 (14) 0·813 
Quality of life    
       Overall score 51 [34, 69] 43 [27, 59] <0·001 
Laboratory data    
       NT-proBNP (pg/mL) 2550 [1103, 5178] 3135 [1369, 6717] <0·001 
       Hemoglobin (g/dL) 13·6 [12·2, 14·7] 12·70 [11·3, 13·9] <0·001 
       Creatinine (µmol/L) 101 [83, 125] 105 [86, 142] <0·001 
       Sodium (mmol/L) 140 [137, 142] 139 [136, 141] <0·001 
       Potassium (mmol/L) 4·2 [3·9, 4·6] 4·2 [3·9, 4·6] 0·09 
Baseline medication (%)    
       ACE or ARB 1279 (75) 541 (67) <0·001 
       B-Blocker  1451 (85) 642 (80) 0·001 
       MRA 966 (57) 373 (46) <0·001 
       Diuretics 1703 (100) 801 (99) 0·68 
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* Coronary artery disease: previous myocardial infarction, percutaneous coronary intervention (PCI) and/or coronary artery 530 
bypass graft (CABG). BMI=body mass index, NYHA=New York Heart Association, LVEF=left ventricular ejection fraction, 531 
BP = blood pressure, COPD=chronic obstructive pulmonary disease,  NT-proBNP=N-terminal pro-B-type natriuretic peptide, 532 
ACE=angiotensin converting enzyme inhibitor, ARB=angiotensin receptor blocker, MRA=mineralocorticoid receptor 533 
antagonist.534 
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Table S3. Baseline characteristics of included and excluded patients (ASIAN-HF). 
 Included Excluded p-value 
 n=4500 n=776 
 
Clinical    
       Age 60 ± 13 60 ± 13 0·27 
       Women (%) 961 (21) 192 (25) 0·039 
       Weight (kg) 68 ± 16 66 ± 16 0·06 
       Height (cm) 164 ± 9 163 ± 9 0·006 
       BMI (kg/m2) 24·9 ± 5·1 24·7 ± 5·4 0·29 
       NYHA (%) 
  
<0·001 
I 556 (14) 57 (8) 
 
II 2116 (52) 387 (55) 
 
III 1154 (28) 223 (32) 
 
IV 255 (6) 36 (5) 
 
       LVEF, % 27 ± 7 27 ± 7 0·63 
       Systolic blood pressure, mmHg  118 ± 20 121 ± 21 <0·001 
       Diastolic blood pressure, mmHg  72 ± 12 74 ± 13 <0·001 
       Heart rate, beats/min 81 ± 19 84 ± 20 <0·001 
History of (%)    
       Coronary artery disease* 2289 (51) 339 (45) 0·005 
       Atrial fibrillation 831 (19) 110 (15) 0·014 
       Stroke  302 (7) 36 (5) 0·06 
       Peripheral art. disease  157 (4) 22 (3) 0·51 
       Hypertension 2323 (52) 396 (59) 0·59 
       Diabetes mellitus  1841 (41) 279 (37) 0·06 
       COPD  367 (8) 67 (9) 0·52 
Physical examination (%)    
       Rales  726 (16) 153 (20) 0·004 
       Edema  1012 (23) 229 (31) <0·001 
       Hepatomegaly 238 (5) 48 (6) 0·25 
Quality of life    
       Overall score 67 [47, 84] 65 [44, 81] 0·004 
Laboratory data    
       Hemoglobin (g/dL) 13·2 [11·7, 14·6] 13·1 [11·6, 14·6] 0·860 
       Creatinine (mg/dL) 1·1 [0·90, 1·44] 1·2 [0·9, 1·6] 0·001 
       Sodium (mmol/L) 139 [136, 141] 138 [135, 140] <0·001 
       Potassium (mmol/L) 4·2 [3·9, 4·6] 4·2 [3·8, 4·5] 0·021 
Baseline medication (%)    
       ACE or ARB 3236 (72) 417 (74) 0·44 
       B-Blocker  3497 (79) 442 (70) <0·001 
       MRA 2685 (60) 313 (40) <0·001 
       Diuretics 3696 (82) 490 (76) <0·001 
* Coronary artery disease: previous myocardial infarction, percutaneous coronary intervention (PCI) and/or coronary artery bypass graft 
(CABG), BMI=body mass index, NYHA=New York Heart Association, LVEF=left ventricular ejection fraction, BP = blood pressure, 
COPD=chronic obstructive pulmonary disease, ACE=angiotensin converting enzyme inhibitor, ARB=angiotensin receptor blocker, 
MRA=mineralocorticoid receptor antagonist. 
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Table S4. Clinical characteristics of men and women at 9 months in BIOSTAT-CHF. 
 
 
Men Women p-value 
Follow-up visit     
       Weight (kg) 86 ± 19 73 ± 16 <0·001 
       Systolic blood pressure, mmHg  124 ± 20 125 ± 21 0·32 
       Diastolic blood pressure, mmHg  75 ± 12 75 ± 12 0·48 
       Heart rate, beats/min 72 ± 15 73 ± 14 0·55 
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Table S5. Overview of individual drug intake by men and women. 
 Men n, % Women n, % 
ACE-inhibitor   
       Ramipril  
565 (47) 143 (39) 
       Enalapril 
163 (14) 48 (13) 
       Perindopril  
162 (14) 61 (17) 
       Lisinopril 
36 (3) 9 (3) 
       Fosinopril  
38 (3) 8 (2) 
       Trandolapril 
17 (1) 3 (1) 
       Quinapril  
14 (1) 3 (1) 
       Captopril 
15 (1) 1 (1) 
ARB   
       Candesartan 
58 (5) 30 (8) 
       Valsartan  
46 (4) 22 (6) 
       Losartan 
31 (3) 18 (5) 
       Irbesartan 
18 (2) 6 (2) 
       Telmisartan 
9 (1) 4 (1) 
Beta-blocker   
       Carvedilol 
495 (40) 119 (32) 
       Bisoprolol 
448 (36) 144 (39) 
       Metoprolol 
229 (19) 84 (23) 
       Nebivolol 
52 (4) 19 (5) 
       Atenolol 
5 (1) 1 (1) 
ACE=angiotensin converting enzyme inhibitor, ARB=angiotensin receptor blocker. 
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Table S6. Baseline characteristics of men and women in ASIAN-HF. 
 
 Men Women p-value 
 (n=3,539) (n=961)  
Clinical    
       Age  60 ± 13 61 ± 14 0·006 
       Weight (kg) 70 ± 15 59 ± 13 <0·001 
       Height (cm) 167 ± 7 155 ± 7 <0·001 
       BMI (kg/m2) 25·1 ± 5·0 24·5 ± 5·2 0·006 
       NYHA (%)   <0·001 
I 467 (15) 89 (10)  
II 1668 (52) 448 (52)  
III 884 (28) 270 (31)  
IV 195 (6) 60 (7)  
       LVEF, % 27 ± 7 29 ± 7 <0·001 
       Systolic blood pressure, mmHg  118 ± 20 119 ± 21 0·12 
       Diastolic blood pressure, mmHg  72 ± 12 71 ± 12 <0·001 
       Pulse pressure, mmHg 45 ± 15 48 ± 16 <0·001 
       Heart rate, beats/min  81 ± 19 82 ± 19 0·009 
       Smoking (%)   <0·001 
                     Never 1613 (46) 876 (91)  
                     Past 1364 (39) 60 (6)  
                     Current 560 (16) 25 (3)  
History of (%)    
       Coronary artery disease* 1953 (55) 336 (35) <0·001 
       Atrial fibrillation 670 (19) 161 (17) 0·14 
       Stroke  243 (7) 59 (6) 0·47 
       Peripheral art. disease  133 (4) 24 (3) 0·07 
       Hypertension 1854 (52) 469 (49) 0·05 
       Diabetes mellitus  1470 (42) 371 (39) 0·11 
       COPD  293 (8) 74 (8) 0·61 
Physical examination (%)    
       Rales  587 (17) 139 (15) 0·12 
       Edema  797 (23) 215 (22) 0·95 
       Hepatomegaly  199 (6) 39 (4) 0·07 
Quality of life    
       Clinical summary score 74 [55, 90] 69 [50, 86] <0·001 
       Overall score 68 [49, 84] 64 [43, 81] <0·001 
Laboratory data    
       Hemoglobin (g/dL)  13·4 [11·9, 14·8] 12·2 [10·8, 13·4] <0·001 
       Creatinine (mg/dL) 1·14 [0·92, 1·48] 0·94 [0·75, 1·24] <0·001 
       Sodium (mmol/L) 139 [136, 141] 139 [136, 141] 0·02 
       Potassium (mmol/L) 4·2 [3·9, 4·6] 4·2 [3·9, 4·6] 0·34 
Medications (%)    
       ACE or ARB 2559 (72) 677 (70) 0·27 
       B-Blocker  2779 (79) 718 (75) 0·009 
       MRA 2141 (61) 544 (57) 0·03 
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       Diuretics 2901 (82) 795 (83) 0·62 
* Coronary artery disease: previous myocardial infarction, percutaneous coronary intervention (PCI) and/or coronary artery bypass graft 
(CABG), BMI=body mass index, NYHA=New York Heart Association, LVEF=left ventricular ejection fraction, BP = blood pressure, 
COPD=chronic obstructive pulmonary disease, ACE=angiotensin converting enzyme inhibitor, ARB=angiotensin receptor blocker, 
MRA=mineralocorticoid receptor antagonist.
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Table S7. Baseline characteristics of men and women using 0-49% versus 50-≥100% of recommended target doses of ACE-inhibitors/ARBs. 
 Men  Women  
 0-49% of target dose 50-≥100% of target dose p-value 0-49% of target dose 50-≥100% of target dose p-value 
 n=598 n=710  n=173 n=229  
Clinical       
       Age  70 ± 12 69 ± 11 0·02 74 ± 13 74 ± 11 0·81 
       Weight (kg) 82 ± 16 88 ± 18 <0·001 70 ± 17 73 ± 16 0·07 
       Height (cm) 174 ± 7 175 ± 8 0·004 162 ± 7 162 ± 7 0·71 
       BMI (kg/m2) 27·2 ± 4·8 28·6 ± 5·5 <0·001 26·8 ± 6·0 27·8 ± 5·6 0·08 
       NYHA (%)   0·15   0·09 
I 57 (11) 63 (10)  9 (6) 25 (13)  
II 274 (51) 365 (58)  75 (50) 97 (49)  
III 187 (35) 185 (29)  57 (38) 73 (37)  
IV 18 (3) 20 (3)  8 (5) 4 (2)  
       LVEF, % 26 ± 7 27 ± 7 0·006 28 ± 6 30 ± 6 0·005 
       Systolic blood pressure, mmHg  118 ± 19 127 ± 20 <0·001 121 ± 23 130 ± 22 <0·001 
       Diastolic blood pressure, mmHg  73 ± 12 78 ± 12 <0·001 72 ± 13 77 ± 13 <0·001 
       Heart rate, beats/min 83 ± 20 81 ± 22 0·12 81 ± 19 84 ± 21 0·11 
       Smoking (%)   0·91   0·75 
                     Never 173 (29) 198 (28)  109 (63) 136 (59)  
                     Past 328 (55) 397 (56)  47 (27) 67 (29)  
                     Current 96 (16) 114 (16)  17 (10) 26 (11)  
History of (%)       
       Coronary artery disease* 294 (49) 337 (48) 0·58 75 (43) 64 (28) 0·002 
       Valvular surgery  56 (9) 39 (6) 0·01 16 (9) 9 (4) 0·05 
       Atrial fibrillation 289 (48) 285 (40) 0·004 67 (39) 73 (32) 0·19 
       Peripheral art. disease  67 (11) 73 (10) 0·65 16 (9) 6 (3) 0·008 
       Hypertension 299 (50) 460 (65) <0·001 106 (61) 147 (64) 0·62 
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       Diabetes mellitus  182 (30) 249 (35) 0·09 46 (27) 63 (28) 0·93 
       COPD  123 (21) 113 (16) 0·04 18 (10) 34 (15) 0·24 
       Renal disease  195 (33) 137 (19) <0·001 45 (26) 33 (14) 0·005 
Physical examination (%)       
       Rales  339 (57) 299 (43) <0·001 95 (56) 110 (50) 0·28 
       Edema  292 (58) 303 (53) 0·10 75 (53) 100 (54) 0·92 
       Orthopnea 195 (33) 193 (27) 0·04 69 (40) 68 (30) 0·04 
       Hepatomegaly  120 (20) 86 (12) <0·001 20 (12) 20 (9) 0·43 
Quality of life       
       Overall score 50 [31, 67] 57 [40, 74] <0·001 42 [27, 56] 46 [32, 62] 0·04 
Laboratory data       
       NT-proBNP (pg/mL) 2983 [1267, 6425] 2122 [912, 4359] <0·001 3056 [1399, 7673] 2430 [937, 4771] 0·002 
       Hemoglobin (g/dL) 13·6 [12·2, 14·8] 14·0 [12·8, 15·1] <0·001 12·8 [11·5, 13·6] 13·0 [12·1, 14·0] 0·03 
       Creatinine (µmol/L) 109 [91, 143] 102 [86, 123] <0·001 95 [76, 121] 83 [71, 104] <0·001 
       Sodium (mmol/L) 139 [137, 141] 140 [137, 142] 0·02 140 [138, 142] 140 [138, 142] 0·13 
       Potassium (mmol/L) 4·3 [4·0, 4·6] 4·3 [4·0, 4·6] 0·63 4·2 [3·9, 4·7] 4·1 [3·7, 4·5] 0·12 
Baseline medication (%)       
       ACE or ARB 416 (70) 572 (81) <0·001 113 (65) 178 (78) 0·008 
       B-Blocker  509 (85) 614 (87) 0·53 143 (83) 185 (81) 0·73 
       MRA 369 (62) 406 (57) 0·11 95 (55) 96 (42) 0·01 
       Diuretics 594 (99) 708 (100) 0·53 173 (100) 228 (100) 1·00 
* Coronary artery disease: previous myocardial infarction, percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG), BMI=body mass index, NYHA=New York Heart Association, 
LVEF=left ventricular ejection fraction, BP = blood pressure, COPD=chronic obstructive pulmonary disease, ACE=angiotensin converting enzyme inhibitor, ARB=angiotensin receptor blocker, 
MRA=mineralocorticoid receptor antagonist.
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Table S8. Baseline characteristics of men and women using 0-49% versus 50-≥100% of recommended target doses of β-blockers. 
 Men  Women  
 0-49% of target dose 50-≥100% of target dose p-value 0-49% of target dose 50-≥100% of target dose p-value 
 n=824 n=484  n=265 n=137  
Clinical       
       Age  70 ± 12 69 ± 12 0·33 74 ± 12 74 ± 12 0·68 
       Weight (kg) 83 ± 18 88 ± 18 <0·001 70 ± 16 76 ± 16 0·001 
       Height (cm) 174 ± 7 176 ± 8 <0·001 161 ± 7 164 ± 7 <0·001 
       BMI (kg/m2) 27·6 ± 5·1 28·4 ± 5·4 0·007 27·0 ± 5·8 28·0 ± 5·6 0·10 
       NYHA (%)   0·53   0·47 
I 72 (10) 48 (11)  19 (8) 15 (13)  
II 406 (56) 233 (53)  115 (49) 57 (50)  
III 234 (32) 138 (32)  90 (39) 40 (35)  
IV 20 (3) 18 (4)  9 (4) 3 (3)  
       LVEF, % 27 ± 7 27 ± 7 0·12 29 ± 6 28 ± 7 0·27 
       Systolic blood pressure, mmHg  122 ± 20 124 ± 21 0·09 126 ± 23 128 ± 23 0·46 
       Diastolic blood pressure, mmHg  75 ± 12 77 ± 13 <0·001 74 ± 13 76 ± 14 0·15 
       Heart rate, beats/min 81 ± 20 83 ± 22 0·04 81 ± 19 86 ± 21 0·02 
       Smoking (%)   0·91   0·09 
                     Never 232 (28) 139 (29)  171 (65) 74 (54)  
                     Past 456 (55) 269 (56)  66 (25) 48 (35)  
                     Current 135 (16) 75 (16)  28 (11) 15 (11)  
History of (%)       
       Coronary artery disease* 412 (50) 219 (45) 0·11 83 (31) 56 (41) 0·07 
       Valvular surgery  58 (7) 37 (8) 0·77 16 (6) 9 (7) 1·00 
       Atrial fibrillation 334 (41) 240 (50) 0·002 80 (30) 60 (44) 0·009 
       Peripheral art. disease  107 (13) 33 (7) 0·001 13 (5) 9 (7) 0·64 
       Hypertension 477 (58) 282 (58) 0·94 167 (63) 86 (63) 1·00 
       Diabetes mellitus  281 (34) 150 (31) 0·27 74 (28) 35 (26) 0·70 
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       COPD  153 (19) 83 (17) 0·57 38 (14) 14 (10) 0·31 
       Renal disease  213 (26) 119 (25) 0·66 52 (20) 26 (19) 0·98 
Physical examination (%)       
       Rales  433 (54) 205 (43) 0·001 137 (53) 68 (51) 0·85 
       Edema  387 (57) 208 (53) 0·23 111 (53) 64 (56) 0·71 
       Orthopnea 271 (33) 117 (24) 0·001 87 (33) 50 (37) 0·55 
       Hepatomegaly  141 (17) 65 (13) 0·09 30 (11) 10 (7) 0·27 
Quality of life       
       Overall score 53 [34, 70] 55 [38, 73] 0·05 43 [30, 58] 46 [32, 64] 0·15 
Laboratory data       
       NT-proBNP (pg/mL) 2527 [1132, 5003] 2435 [957, 5087] 0·40 2637 [1157, 5640] 2938 [1417, 6756] 0·21 
       Hemoglobin (g/dL) 13·8 [12·3, 14·8] 14·0 [12·7, 15·1] 0·03 12·9 [11·8, 13·9] 12·8 [11·8, 13·8] 0·84 
       Creatinine (µmol/L) 106 [88, 132] 103 [88, 128] 0·16 88 [72, 108] 88 [71, 113] 0·78 
       Sodium (mmol/L) 140 [137, 142] 140 [138, 142] 0·02 140 [138, 142] 140 [138, 142] 0·87 
       Potassium (mmol/L) 4·3 [4·0, 4·6] 4·3 [4·0, 4·6] 0·80 4·2 [3·8, 4·6] 4·2 [3·7, 4·5] 0·39 
Baseline medication (%)       
       ACE or ARB 619 (75) 369 (76) 0·70 192 (73) 99 (72) 1·00 
       B-Blocker  674 (82) 449 (93) <0·001 205 (77) 123 (90) 0·004 
       MRA 513 (62) 262 (54) 0·005 129 (49) 62 (45) 0·59 
       Diuretics 818 (99) 484 (100) 0·15 265 (100) 136 (99) 0·74 
* Coronary artery disease: previous myocardial infarction, percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG), BMI=body mass index, NYHA=New York Heart Association, 
LVEF=left ventricular ejection fraction, BP = blood pressure, COPD=chronic obstructive pulmonary disease, ACE=angiotensin converting enzyme inhibitor, ARB=angiotensin receptor blocker, 
MRA=mineralocorticoid receptor antagonist. 
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Table S9. The number of men and women reaching specific dose level combinations of ACE-
inhibitors/ARBs and β-blockers in BIOSTAT-CHF and ASIAN-HF. 
BIOSTAT-CHF 
 
 
 
Men 
n=1,308 
Women 
n=402 
ACE-i/ARB dose: β-blocker dose:   
Target dose  Target dose 58 (4%) 19 (5%) 
50-100%  50-100%  317 (24%) 88 (22%) 
50-100%  0-49% 393 (30%) 141 (35%) 
0-49%  50-100% 167 (13%) 49 (12%) 
0-49%  0-49% 431 (33%) 124 (31%) 
    
ASIAN-HF 
 
 
 
Men 
n=3,539 
Women 
n=961 
ACE-i/ARB dose: β-blocker dose:   
Target dose  Target dose 77 (2%) 22 (2%) 
50-100%  50-100% 384 (11%) 103 (11%) 
50-100%  0-49% 724 (20%) 194 (20%) 
0-49%  50-100% 584 (17%) 135 (14%) 
0-49%  0-49% 1790 (51%) 516 (54%) 
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Table S10. Overview of the reasons why men and women were not using target doses of ACE-
inhibitors/ARBs and β-blockers after the up-titration period of BIOSTAT-CHF. 
ACE-inhibitors/ARBs reason (%) 
Men 
n=1308 
Women 
n=402 
p-value 
On target dose 304 (23) 99 (25) 0·61 
Not on target dose 1004 (77) 303 (75) 
     Symptoms/side effects/non-cardiac organ dysfunction 118 (12) 48 (16) 0·039 
     Not-specified/unknown 886 (88) 255 (84) 
β-blockers reason (%) 
 
On target dose 168 (13) 57 (14) 0·54 
Not on target dose 1140 (87) 345 (86) 
     Symptoms/side effects/non-cardiac organ dysfunction 103 (9) 36 (10) 0·13 
     Not-specified/unknown 1037 (91) 309 (90) 
ACE=angiotensin converting enzyme inhibitor, ARB=angiotensin receptor blocker. 
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Figure S1. Flow diagram of selected patients. 
 
 
 
BIOSTAT-CHF= the BIOlogy Study to TAilored Treatment in Chronic Heart Failure, LVEF=left ventricular ejection fraction, HFrEF=heart 
failure with reduced ejection fraction.
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Figure S2. Density plot of the dose levels used in BIOSTAT-CHF (blue) and ASIAN-HF (red).
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Figure S3. Subpopulation treatment effect pattern plot (STEPP) of men and women per % of 
recommended beta-blockers (3A) and ACE-inhibitors/ARBs (3B) dose in BIOSTAT-CHF, and the ratio of 
the relative risk of women divided by the relative risk in men for beta-blockers (3C) and ACE-
inhibitors/ARBs (3D), resulting in a hazard ratio for women compared with men, including confidence 
intervals of this ratio. 
 
   3A           3B 
    3C           3D 
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Shunsuke Kiuchi, Tokyo Women's Medical University: Nobuhisa Hagiwara, Atsushi Suzuki, Dr. Tsuyoshi 
Suzuki.  
Korea 
SeJong General Hospital: Sang-Weon Park (Country PI), Suk Keun Hong, SookJin Lee, Lim Dal Soo, Dong-
Hyeok Kim. Korea University Anam Hospital: Jaemin Shim, Seong-Mi Park, Seung-Young Roh, Young Hoon 
Kim, Mina Kim, Jong-Il Choi. Korea University Guro Hospital: Jin Oh Na, Seung Woon Rha, Hong Seog Seo, 
Dong Joo Oh, Chang Gyu Park, Eung Ju Kim, Sunki Lee, Severance Hospital, Yonsei University Health System: 
Boyoung Joung, Jae-Sun Uhm, Moon Hyoung Lee, In-Jeong Cho, Hui-Nam Park. Chonnam National University 
Hospital: Hyung-Wook Park, Jeong-Gwan Cho, Namsik Yoon, KiHong Lee, Kye Hun Kim. Korea University 
Ansan Hospital: Seong Hwan Kim.  
Malaysia 
Hospital Queen Elizabeth II: Houng Bang Liew (Country PI), Sahrin Saharudin, Boon Cong Beh, Yu Wei Lee, 
Chia How Yen, Mohd Khairi Othman, Amie-Anne Augustine, Mohd Hariz Mohd Asnawi, Roberto Angelo 
Mojolou, You Zhuan Tan, Aida Nurbaini Arbain, Chii Koh Wong. Institut Jantung Negara: Razali Omar, Azmee 
Mohd Ghazi, Surinder Kaur Khelae, David S.P. Chew, Lok Bin Yap, Azlan Hussin, Zulkeflee Muhammad, 
Mohd. Ghazi Azmee. University Malaya Medical Centre: Imran Zainal Abidin, Ahmad Syadi Bin Mahmood 
Zhudi, Nor Ashikin Md Sari, Ganiga Srinivasaiah Sridhar, Ahmad Syadi Mahmood Zuhdi. Muhammad Dzafir 
Ismail. Sarawak General Hospital Heart Centre: Tiong Kiam Ong, Yee Ling Cham, Ning Zan Khiew, Asri Bin 
Said, Alan Yean Yip Fong, Nor Hanim Mohd Amin, Keong Chua Seng, Sian Kong Tan, Kuan Leong Yew.  
Philippines 
Manila Doctors Hospital: Eugenio Reyes (Country PI), Jones Santos, Allan Lim. Makati Medical Center: Raul 
Lapitan, Ryan Andal, Philippine Heart Center: Eleanor Lopez.  
Singapore 
National Heart Centre Singapore: Carolyn S.P. Lam (Country PI), Kheng Leng David Sim, Boon Yew Tan, 
Choon Pin Lim, Louis L.Y. Teo, Laura L.H. Chan. National University Heart Centre: Lieng Hsi Ling, Ping Chai, 
Ching Chiew Raymond Wong, Kian Keong Poh, Tan Tock Seng Hospital: Poh Shuan Daniel Yeo, Evelyn M. 
Lee, Seet Yong Loh, Min Er Ching, Deanna Z.L. Khoo, Min Sen Yew, Wenjie Huang. Changi General Hospital-
Parent: Kui Toh Gerard Leong, Jia Hao Jason See, Yaozong Benji Lim, Svenszeat Tan, Colin Yeo, Siang Chew 
Chai. Singapore General Hospital-Parent: Fazlur Rehman Jaufeerally, Haresh Tulsidas, Than Aung. Khoo Teck 
Puat Hospital: Hean Yee Ong, Lee Fong Ling, Dinna Kar Nee Soon  
Taiwan 
Mackay Memorial Hospital, Taipei, Taiwan: Chung-Lieh Hung (Country PI), Hung-I Yeh,Jen-Yuan Kuo, 
Chih-Hsuan Yen. National Taiwan University Hospital: Juey-Jen Hwang, Kuo-Liong Chien, Ta-Chen Su, Lian-
Yu Lin, Jyh-Ming Juang, Yen-Hung Lin, Fu-Tien Chiang, Jiunn-Lee Lin, Yi-Lwun Ho, Chii-Ming Lee, Po-Chih 
Lin, Chi-Sheng Hung, Sheng-Nan Chang, Jou-Wei Lin, Chih-Neng Hsu. Taipei Veterans General Hospital: 
Wen-Chung Yu, Tze-Fan Chao, Shih-Hsien Sung, Kang-Ling Wang, Hsin-Bang Leu, Yenn-Jiang Lin, Shih-Lin 
Chang, Po-Hsun Huang, Li-Wei Lo, Cheng-Hsueh Wu. China Medical University Hospital: Hsin-Yueh Liang, 
Shih-Sheng Chang, Lien-Cheng Hsiao, Yu-Chen Wang, Chiung-Ray Lu, Hung-Pin Wu, Yen-Nien Lin, Ke-Wei 
Chen, Ping-Han Lo, Chung-Ho Hsu, Li-Chuan Hsieh. 
Thailand 
Ramathibodi Hospital: Tachapong Ngarmukos (Country PI), Mann Chandavimol, Teerapat Yingchoncharoen, 
Prasart Laothavorn. Phramongkutklao Hospital:Waraporn Tiyanon. Maharaj Nakorn Chiang Mai Hospital: 
Wanwarang Wongcharoen, Arintaya Phrommintikul. 
 
 
 
